Drug Trial Radar · NCT01515423
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: May 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,429
Actual
Start
May 2012
Primary completion
Feb 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who have been stabilized on PP1M.
Conditions
- Schizophrenia
Interventions
PP3M 175 mg eq.Drug
Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
PP3M 263 mg eq.Drug
Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
PP3M 350 mg eq.Drug
Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
PP3M 525 mg eq.Drug
Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Placebo (20% Intralipid)Drug
Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
PP1M 50 mg eq.Drug
Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
PP1M 75 mg eq.Drug
Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
PP1M 100 mg eq.Drug
Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
PP1M 150 mg eq.Drug
Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Without Relapse at Week 48 During the Double-Blind PhaseTime frame: Up to 48 weeks
Locations
174 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Glendale, California
Site not named
Long Beach, California
Site not named
Oakland, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
San Diego, California
Site not named
New Britain, Connecticut
Site not named
Bradenton, Florida
Site not named
Kissimmee, Florida
Site not named
Tampa, Florida
Site not named
Wichita, Kansas
Site not named
East Lansing, Michigan
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
Jamaica, New York
Site not named
Durham, North Carolina
Site not named
Canton, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Memphis, Tennessee
Site not named
Austin, Texas
Site not named
Bothell, Washington
Site not named
Buenos Aires, Argentina
Site not named
Córdoba, Argentina
Site not named
Rosario, Argentina
Site not named
Elizabeth Vale, Australia
Site not named
Frankston, Australia
Site not named
Innsbruck, Austria
Site not named
Assebroek, Belgium
Site not named
Bertrix, Belgium
Site not named
Dave, Belgium
Site not named
Heusden, Belgium
Site not named
Jette, Belgium
Site not named
Marchienne-au-Pont, Belgium
Site not named
Sint-Denijs-Westrem, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Burgas, Bulgaria
Site not named
Kazanlak, Bulgaria
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.